Drug intelligence / Profile preview

Remegal

Development stage: Phase 3
Lead developer: Valexfarm
Administration: Oral

Overview

Remegal is a drug developed by Valexfarm. It is being investigated as an adjunctive therapy for patients with epilepsy experiencing partial seizures. A double-blind, placebo-controlled clinical study is underway to evaluate its efficacy, safety, and tolerability in this patient population.

Targets

MTNR1A (MT1)

Beyond the preview

Go deeper on Remegal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Remegal.

Explore the full profile